ArticleOncogene2012
miR-296 regulation of a cell polarity-cell plasticity module controls tumor progression.
Article in Oncogene, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 91 citations in OpenAlex.
- Metformin alleviates intervertebral disc degeneration by upregulating MMP-1 expression via the KDM6A/SOX9/miR-202-3p/MMP-1 signaling pathway.Archives of medical science : AMS · 2026Article
- Quantitative determination of the spatial distribution of components in single cells with CellDetail.Nature communications · 2024Article
- Molecular profile of bladder cancer progression to clinically aggressive subtypes.Nature reviews. Urology · 2024Review
- MPP7 mediates EMT via Wnt/β-catenin pathway to promote polarity changes in epithelial ovarian cancer cells.Journal of Cancer · 2024Article
- Article
- Characterization of MicroRNA expression profiles in the ovarian tissue of goats during the sexual maturity period.Journal of ovarian research · 2023Article
- A common variant SNP rs1937810 in the MPP7 gene contributes to the susceptibility of breast cancer in the Chinese Han population.Molecular genetics & genomic medicine · 2023Article
- Comparative analysis of microRNA and messengerRNA expression profiles in plateau zokor testicular cells under reproductive suppression.Frontiers in veterinary science · 2023Article
- Clinicopathological Review of Micropapillary Urothelial Carcinoma.Current oncology reports · 2022Review
- MicroRNA Profile Alterations in Parathyroid Carcinoma: Latest Updates and Perspectives.Cancers · 2022Review
- miR-296-5p Inhibits the Secretion of Pulmonary Surfactants in Pulmonary Epithelial Cells via the Downregulation of Wnt7b/BioMed research international · 2021Article
- Seasonal effects on miRNA and transcriptomic profile of oocytes and follicular cells in buffalo (Bubalus bubalis).Scientific reports · 2020Article
- Screening of differentially expressed miRNAs in tensile strain‑treated HepG2 cells by miRNA microarray analysis.Molecular medicine reports · 2020Article
- Targeting of oncogenic signaling pathways by berberine for treatment of colorectal cancer.Medical oncology (Northwood, London, England) · 2020Review
- Developments in oligometastatic hormone-sensitive prostate cancer.World journal of urology · 2019Article
- MicroRNA-296: a promising target in the pathogenesis of atherosclerosis?Molecular medicine (Cambridge, Mass.) · 2018Review
- The Unknown microRNA Expression of Male Breast Cancer. Similarities and Differences with Female Ductal Carcinoma. Their Role as Tumor Biomarker.Journal of Cancer · 2018Article
- Epigenetic silencing of miR-296 and miR-512 ensures hTERT dependent apoptosis protection and telomere maintenance in basal-type breast cancer cells.Oncotarget · 2017Article
- miR-494-3p is a novel tumor driver of lung carcinogenesis.Oncotarget · 2017Article
- Gene Expression Profile of the Clinically Aggressive Micropapillary Variant of Bladder Cancer.European urology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
Abstract
The expression of small, non-coding RNA or microRNAs (miR), is frequently deregulated in human cancer, but how these pathways affect disease progression is still largely elusive. Here, we report on a miR, miR-296, which is progressively lost during tumor progression and correlates with metastatic disease in colorectal, breast, lung, gastric, parathyroid, liver and bile ducts cancers. Functionally, miR-296 controls a global cell motility gene signature in epithelial cells by transcriptionally repressing the cell polarity-cell plasticity module, Scribble (Scrib). In turn, loss of miR-296 causes aberrantly increased and mislocalized Scrib in human tumors, resulting in exaggerated random cell migration and tumor cell invasiveness. Re-expression of miR-296 in MDA-MB231 cells inhibits tumor growth in vivo. Finally, miR-296 or Scrib levels predict tumor relapse in hepatocellular carcinoma patients. These data identify miR-296 as a global repressor of tumorigenicity and uncover a previously unexplored exploitation of Scrib in tumor progression in humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.